X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1231) 1231
humans (1124) 1124
abiraterone acetate (1107) 1107
prostate cancer (1081) 1081
male (1066) 1066
oncology (754) 754
abiraterone (669) 669
enzalutamide (531) 531
chemotherapy (525) 525
prostatic neoplasms, castration-resistant - drug therapy (514) 514
docetaxel (508) 508
urology & nephrology (443) 443
metastasis (439) 439
cancer (391) 391
increased survival (383) 383
care and treatment (340) 340
aged (332) 332
antineoplastic agents - therapeutic use (323) 323
treatment outcome (311) 311
prostatic neoplasms - drug therapy (301) 301
prostatic neoplasms, castration-resistant - pathology (299) 299
androgen receptor (293) 293
survival (290) 290
middle aged (283) 283
double-blind (280) 280
antitumor-activity (273) 273
castration-resistant prostate cancer (267) 267
castration (257) 257
androgens (248) 248
men (231) 231
prednisone (229) 229
phenylthiohydantoin - analogs & derivatives (223) 223
aged, 80 and over (205) 205
prostatic neoplasms - pathology (197) 197
urology (196) 196
prostate (193) 193
therapy (191) 191
androgen antagonists - therapeutic use (182) 182
cabazitaxel (182) 182
mitoxantrone plus prednisone (179) 179
neoplasm metastasis (178) 178
survival analysis (178) 178
research (177) 177
mitoxantrone (175) 175
pharmacology & pharmacy (173) 173
taxoids - therapeutic use (173) 173
analysis (163) 163
disease-free survival (162) 162
drug therapy (161) 161
receptors, androgen - metabolism (157) 157
antineoplastic combined chemotherapy protocols - therapeutic use (155) 155
plus prednisone (153) 153
article (152) 152
phenylthiohydantoin - therapeutic use (152) 152
disease progression (150) 150
animals (149) 149
cancer therapies (149) 149
metastases (148) 148
retrospective studies (146) 146
medicine & public health (138) 138
health aspects (137) 137
patients (135) 135
prognosis (134) 134
orchiectomy (132) 132
resistant prostate-cancer (131) 131
sipuleucel-t (128) 128
prostate-specific antigen - blood (127) 127
development and progression (126) 126
endocrinology & metabolism (124) 124
metastatic castration-resistant prostate cancer (123) 123
testosterone (119) 119
cyp17 (115) 115
prostatic neoplasms - metabolism (114) 114
prostatic neoplasms, castration-resistant - mortality (114) 114
trial (112) 112
steroid 17-alpha-hydroxylase - antagonists & inhibitors (109) 109
antineoplastic agents, hormonal - therapeutic use (108) 108
androstenes (107) 107
clinical trials (107) 107
drug resistance, neoplasm (107) 107
hematology, oncology and palliative medicine (107) 107
immunotherapy (107) 107
progression (107) 107
prostatic neoplasms, castration-resistant - blood (106) 106
androgen-deprivation therapy (105) 105
abiraterone acetate - therapeutic use (102) 102
open-label (102) 102
androgen deprivation therapy (101) 101
i clinical-trial (101) 101
prostatic neoplasms - therapy (100) 100
urologic and male genital diseases (100) 100
phase-ii (95) 95
bone neoplasms - secondary (92) 92
expression (92) 92
clinical trials as topic (90) 90
receptors, androgen - genetics (90) 90
cell line, tumor (88) 88
prostate-specific antigen (88) 88
clinical-trials (86) 86
review (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1618) 1618
French (55) 55
German (52) 52
Spanish (19) 19
Russian (11) 11
Japanese (5) 5
Dutch (2) 2
Italian (2) 2
Chinese (1) 1
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 5, pp. 1277 - 1284
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 33, pp. 3705 - 3715
Journal Article
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 66, Issue 5, pp. 815 - 825
Abstract Background Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic... 
Urology | Chemotherapy-naive | Efficacy | Safety | Metastatic castration-resistant prostate cancer | Abiraterone acetate | prostate cancer | Metastatic castration-resistant | PLACEBO | DOCETAXEL CHEMOTHERAPY | PHASE-3 | TRIAL | MITOXANTRONE PLUS PREDNISONE | THERAPY | MEN | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | LIFE | Neoplasms, Hormone-Dependent - mortality | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - enzymology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Neoplasms, Hormone-Dependent - enzymology | Prednisone - administration & dosage | Androstenes - adverse effects | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Androstenes - administration & dosage | Cytochrome P-450 Enzyme Inhibitors - administration & dosage | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Steroid 17-alpha-Hydroxylase - metabolism | Neoplasms, Hormone-Dependent - drug therapy | Medical colleges | Cancer patients | Care and treatment | Chemotherapy | Corticosteroids | Analysis | Metastasis | Prostate cancer | Acetates | Cancer | Index Medicus
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 4, pp. 795 - 802
Journal Article
Journal Article
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 1, pp. 10 - 13
Abstract In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic... 
Urology | Androgen signaling–directed therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Sequencing | Abiraterone acetate | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | Chemotherapy-naive | DOCETAXEL | CHEMOTHERAPY | prostate cancer | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Metastatic castration-resistant | Androgen signaling-directed therapy | ENZALUTAMIDE | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Kallikreins - blood | Retrospective Studies | Prednisone - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Steroid Synthesis Inhibitors - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Randomized Controlled Trials as Topic | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Prostatic Neoplasms, Castration-Resistant - mortality | Prednisone - therapeutic use | Medical research | Medical colleges | Care and treatment | Corticosteroids | Patient outcomes | Censorship | Prednisone | Metastasis | Acetates | Chemotherapy | Medicine, Experimental | Prostate cancer | Cancer | Steroids | Index Medicus
Journal Article
Journal Article